Candida auris—the growing menace to global health

• Published in: Mycoses
• Main Authors: Lone, Shabir A., Ahmad, Aijaz
• Other Authors: South African Agency for Science and Technology Advancement, University of the Witwatersrand, Johannesburg
• Format: Article in Journal/Newspaper
• Language: English
• Published: Wiley 2019
• Subjects: Antarc*; Antarctica
• Online Access: http://dx.doi.org/10.1111/myc.12904; https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fmyc.12904; https://onlinelibrary.wiley.com/doi/pdf/10.1111/myc.12904; https://onlinelibrary.wiley.com/doi/full-xml/10.1111/myc.12904

summary A paradigm shift of candidiasis from Candida albicans to non‐albicans Candida species has fundamentally increased with the advent of C. auris . C. auris, despite being a newly emerged multidrug‐resistant fungal pathogen, is associated with severe invasive infections and outbreaks with high mortality rates. Initially reported from Japan in 2009, C. auris have now been found in different countries on all the continents except Antarctica. Due to its capability of nosocomial transmission and forming adherent biofilms on clinically important substrates, a high number of related hospital outbreaks have been reported worldwide. As C. auris is a multidrug‐resistant pathogen and is prone to misidentification by available conventional methods, it becomes difficult to detect and manage C. auris infection and also limits the therapeutic options against this deadly pathogen. The emergence of multidrug‐resistant C. auris advocates and amplifies the vigilance of early diagnosis and appropriate treatment of fungal infections. In this review, we discussed the nine‐year‐old history of C. auris —its trends in global emergence, epidemiological relatedness, isolation, mortality, associated risk factors, virulence factors, drug resistance and susceptibility testing, diagnostic challenges, microbiological characteristics, therapeutic options and infection prevention and control associated with this pathogen.